Roche acquires BioImagene, a leading provider of digital pathology laboratory solutions
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has signed an agreement under which Ventana Medical Systems Inc., a member of the Roche Group, will acquire 100 percent of BioImagene, Inc., a privately held company based in Sunnyvale, California.
GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta®
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE).
Ipilimumab Receives FDA Priority Review Designation
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated.
Lilly Halts Development of Semagacestat for Alzheimer's Disease
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living.
Lundbeck reports strongly increasing profits with EBIT growth of 30%
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) reports second quarter revenue of DKK 3,767 million. An increase of 7% compared to the second quarter results of 2009. Profit from operations was DKK 936 million, an increase of 30% compared to the same period last year.
Abbott Launches New Psoriasisanswers.com Web site
- Details
- Category: Abbott
August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information about what's happening to them can be a challenge.
Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) today announced top-line results from a randomized Phase 3 trial evaluating Vectibix(R) (panitumumab) as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer.
More Pharma News ...
- Pfizer Reports Second-Quarter 2010 Results
- Image of new antibiotic in action opens up new opportunities
- TEMPO study further demonstrates the benefits of Azilect® in early Parkinson's disease patients
- Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen
- Shire Proposes to Expand Specialist Gastrointestinal Portfolio
- AstraZeneca Second Quarter and Half Year Results 2010
- Bayer increases sales and earnings in the second quarter